BIT has the product, I think this is pretty clear from the science. The billion dollar question is whether the board understands the gravitas of what they have and they ensure a good, solid deal follows. Australian biotechs lack the aggressiveness of their international counterparts, particularly compared to the US. This can lead to them selling themselves short.
